Damora Therapeutics, Inc. (DMRA)
30.74
+0.43
(+1.42%)
USD |
NASDAQ |
Aug 25, 16:00
30.74
0.00 (0.00%)
After-Hours: 19:59
Damora Therapeutics Enterprise Value : 1.461B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.461B |
| August 21, 2026 | 1.493B |
| August 20, 2026 | 1.461B |
| August 19, 2026 | 1.593B |
| August 18, 2026 | 1.553B |
| August 17, 2026 | 1.509B |
| August 14, 2026 | 1.506B |
| August 13, 2026 | 1.487B |
| August 12, 2026 | 1.504B |
| August 11, 2026 | 1.464B |
| August 10, 2026 | 1.414B |
| August 07, 2026 | 1.437B |
| August 06, 2026 | 1.435B |
| August 05, 2026 | 1.493B |
| August 04, 2026 | 1.443B |
| August 03, 2026 | 1.353B |
| July 31, 2026 | 1.380B |
| July 30, 2026 | 1.393B |
| July 29, 2026 | 1.339B |
| July 28, 2026 | 1.406B |
| July 27, 2026 | 1.407B |
| July 24, 2026 | 1.369B |
| July 23, 2026 | 1.391B |
| July 22, 2026 | 1.441B |
| July 21, 2026 | 1.627B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.627B |
| July 17, 2026 | 1.533B |
| July 16, 2026 | 1.457B |
| July 15, 2026 | 1.501B |
| July 14, 2026 | 1.503B |
| July 13, 2026 | 1.319B |
| July 10, 2026 | 1.351B |
| July 09, 2026 | 1.490B |
| July 08, 2026 | 1.290B |
| July 07, 2026 | 1.442B |
| July 06, 2026 | 1.430B |
| July 02, 2026 | 1.441B |
| July 01, 2026 | 1.262B |
| June 30, 2026 | 1.196B |
| June 29, 2026 | 1.060B |
| June 26, 2026 | 1.129B |
| June 25, 2026 | 961.01M |
| June 24, 2026 | 926.63M |
| June 23, 2026 | 983.33M |
| June 22, 2026 | 1.040B |
| June 18, 2026 | 880.18M |
| June 17, 2026 | 891.64M |
| June 16, 2026 | 841.57M |
| June 15, 2026 | 810.21M |
| June 12, 2026 | 853.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
| Vericel Corp. | 2.097B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.17M |
| Total Expenses (Quarterly) | 31.17M |
| EPS Diluted (Quarterly) | -0.5099 |
| Earnings Yield | -405.9% |
| Normalized Earnings Yield | -166.46 |